Association between Hypoxia Inducible Factor Prolyl Hydoxylase Inhibitor or Erythropoiesis-Stimulating Agents and Cardiovascular Disease: a retrospective cohort study with overlap propensity score weighting

Not Applicable

• Conditions: Renal anemia

• Registration Number: JPRN-UMIN000050850
• Lead Sponsor: Graduate School of Medicine and Public Health, Kyoto University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-09-01
• Study Completion: 2023-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

Not provided

Exclusion Criteria

Patients without a six-month lookback period before the index date. Patients with a diagnosis of CVD prior to the index date (date of first dose of HIF-PH inhibitor or ESA preparation) (see primary endpoint for definition).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The composite outcome of cardiovascular diseases including coronary artery disease (I210-4, I219), stroke (I600-11, I613-6, I619, I629-36, I638-9), heart failure (I500-1, I509, I110), atrial fibrillation (I480-4, I489)

Secondary Outcome Measures

Name	Time	Method
all cause mortality, artery disease (I210-4, I219), stroke (I600-11, I613-6, I619, I629-36, I638-9), heart failure (I500-1, I509, I110), atrial fibrillation (I480-4, I489)